Connetics Olux adds non-scalp psoriasis
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Connetics hopes to significantly expand the market for Olux (clobetasol propionate, 0.05%) with the Dec. 20 approval of the topical corticosteroid foam for short-term treatment of mild to moderate non-scalp psoriasis (excluding the face and intertriginous areas). The company estimates that approximately 80% of all prescriptions for psoriasis are for areas other than the scalp. Olux was previously approved for steroid-responsive scalp dermatose
You may also be interested in...
Merck’s ‘COVID Pill’ Shows Promise, But Mortality Benefits Will Be Hard To Prove
Early results from its novel antiviral are encouraging, but demonstrating life-saving qualities in a short window of time will be tricky.
ROI For US With FDA's Emergency Use Approval Of Cue Health's OTC At-Home COVID-19 Test
After federal agencies invested almost $5600m to ensure Cue Health could scale up production, FDA announces the self-administered test will be available OTC. it's the agency's first emergency use authorization for an at-home molecular diagnostic test available nonprescription.
AstraZeneca & Amgen Seek EU Fast-Track For Severe Asthma Drug
Tezepelumab was among four products that the European Medicines Agency most recently considered for review under its accelerated assessment mechanism.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: